SAM Chun Dang Pharm

At a glance

SAM Chun Dang Pharm filed 47 disclosures in the last 12 months, including 3 5% holder. The most recent key filing was on Oct 20: A major holder's stake rose from 37.61% to 37.61% (pledge).

Revenue for 2025 was ₩232B, up 9.9% on 2024. Operating margin was 3.7% against 1.3% a year earlier. Debt was 54% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩136B and operating profit of ₩8.9B.

The 2025 annual report lists 436 employees with an average tenure of 8.3 years and average pay of ₩65.8M, #730 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩54.6M each on average. It paid ₩50 per common share in cash dividends, against ₩200 a year earlier (-75%). (주)소화 and related parties held 37.60% at year end.

Of 1 recent 5%+ holder report, 0 raised and 0 cut a stake; the largest stake reported was 37.61% on Oct 20.

From the 2025 annual report

Staff: 436 (306 men, 130 women), of whom 10 on fixed-term contracts. Total pay for the year: ₩28.7B. Directors and auditors: 8, paid ₩436.9M in total.

Dividends (common shares)

Largest shareholder

(주)소화 holds 30.70%; with 3 related parties the group holds 37.60% of common shares at year end.

Auditor: 선진회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports